<DOC>
	<DOCNO>NCT00887107</DOCNO>
	<brief_summary>The purpose study ass whether therapy Sorafenib reinduces radioiodine uptake thyroid carcinoma .</brief_summary>
	<brief_title>Sorafenib Adjuvant Radioiodine Therapy Non-Medullary Thyroid Carcinoma</brief_title>
	<detailed_description>Background study : Therapy radioiodine ( RaI ) curative therapy non-medullary thyroid carcinoma . RaI uptake frequently lose disease . Therapy tyrosine kinase inhibitor may restore susceptibility RaI . Objective study : To investigate whether therapy tyrosine kinase inhibitor Sorafenib increase accumulation radioiodine ( RaI ) decrease tumor progression patient recurrences metastasis non-medullary thyroid carcinoma absent insufficient accumulation RaI . Study design : Prospective , open study patient recurrences metastasis differentiate thyroid carcinoma undergo 6 month therapy Sorafenib 800 mg/day . Patients RaI uptake restore offer high dose ( 6000 MBq ) RaI together additional 6 month treatment Sorafenib . Patients RaI restore Sorafenib favorable effect tumor growth offer continued treatment Sorafenib . Study population : Thirty patient include recurrence metastasis differentiate thyroid carcinoma unresponsive RaI therapy . Intervention ( applicable ) : After inclusion , patient undergo 131I scintigraphy well CT scan . Thereafter , therapy Sorafenib 800 mg/day initiate , continue 6 month . After 6 month , 131I scintigraphy CT scan repeat . Serum level thyroglobulin use tumormarker . Primary study parameters/outcome study : The endpoint study proportion patient favorable response Sorafenib define ONE OR MORE following criterion : 1 . Reinduction RaI uptake RaI scintigraphy : The appearance one RaI accumulate lesion RaI scintigraphy , planar image and/or SPECT ( see ) 2 . Serum thyroglobulin level : The absence progression : statistically significant positive slope linear regression log-transformed serum Tg level , measure 0 , 4 , 8 , 12 , 16 , 20 , 24 28 week start Sorafenib : - Stable disease : The slope linear regression log-transformed serum Tg level , measure 0 , 4 , 8 , 12 , 16 , 20 , 24 28 week start Sorafenib significantly different 0 ln ug/L*time OR - Response : The slope linear regression log-transformed serum Tg level negative ( statistically significantly 0 ln ug/L*time ) . 3 . CT Imaging : The absence progression accord RECIST criterion : - Stable disease—neither sufficient shrinkage qualify partial response sufficient increase qualify progressive disease , take reference small sum long diameter since treatment start . - Partial response—at least 30 % decrease sum long diameter target lesion , take reference baseline sum long diameter ; - Complete response : disappearance target lesion</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients nonmedullary thyroid carcinoma The patient must undergo total thyroidectomy Presence metastasis inoperable recurrent disease , proven elevate serum thyroglobulin level ( Tg ) combination radiological evidence tumor No insufficient RaI uptake tumor proven RaI scintigraphy , perform prior RaI therapy Pregnancy Other active malignancy Active kidney , liver pancreatic disease dysfunction Unstable angina pectoris recent ( &lt; 3 month ) myocardial infarction . Coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>